128 related articles for article (PubMed ID: 28100394)
1. Replication Study: Melanoma genome sequencing reveals frequent
Horrigan SK; Courville P; Sampey D; Zhou F; Cai S;
Elife; 2017 Jan; 6():. PubMed ID: 28100394
[TBL] [Abstract][Full Text] [Related]
2. Registered report: Melanoma genome sequencing reveals frequent PREX2 mutations.
Chroscinski D; Sampey D; Hewitt A;
Elife; 2014 Dec; 3():. PubMed ID: 25490935
[TBL] [Abstract][Full Text] [Related]
3. Interplay between PREX2 mutations and the PI3K pathway and its effect on epigenetic regulation of gene expression in NRAS-mutant melanoma.
Lissanu Deribe Y
Small GTPases; 2016 Jul; 7(3):178-85. PubMed ID: 27111337
[TBL] [Abstract][Full Text] [Related]
4. Melanoma mystery.
Davis RJ
Elife; 2017 Jan; 6():. PubMed ID: 28100393
[TBL] [Abstract][Full Text] [Related]
5. Melanoma genome sequencing reveals frequent PREX2 mutations.
Berger MF; Hodis E; Heffernan TP; Deribe YL; Lawrence MS; Protopopov A; Ivanova E; Watson IR; Nickerson E; Ghosh P; Zhang H; Zeid R; Ren X; Cibulskis K; Sivachenko AY; Wagle N; Sucker A; Sougnez C; Onofrio R; Ambrogio L; Auclair D; Fennell T; Carter SL; Drier Y; Stojanov P; Singer MA; Voet D; Jing R; Saksena G; Barretina J; Ramos AH; Pugh TJ; Stransky N; Parkin M; Winckler W; Mahan S; Ardlie K; Baldwin J; Wargo J; Schadendorf D; Meyerson M; Gabriel SB; Golub TR; Wagner SN; Lander ES; Getz G; Chin L; Garraway LA
Nature; 2012 May; 485(7399):502-6. PubMed ID: 22622578
[TBL] [Abstract][Full Text] [Related]
6. Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.
Lissanu Deribe Y; Shi Y; Rai K; Nezi L; Amin SB; Wu CC; Akdemir KC; Mahdavi M; Peng Q; Chang QE; Hornigold K; Arold ST; Welch HC; Garraway LA; Chin L
Proc Natl Acad Sci U S A; 2016 Mar; 113(9):E1296-305. PubMed ID: 26884185
[TBL] [Abstract][Full Text] [Related]
7. ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.
Ryan MB; Finn AJ; Pedone KH; Thomas NE; Der CJ; Cox AD
Mol Cancer Res; 2016 Oct; 14(10):1009-1018. PubMed ID: 27418645
[TBL] [Abstract][Full Text] [Related]
8. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Aird F; Kandela I; Mantis C;
Elife; 2017 Jan; 6():. PubMed ID: 28100400
[TBL] [Abstract][Full Text] [Related]
9. Replication study: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
Kim J; Afshari A; Sengupta R; Sebastiano V; Gupta A; Kim YH;
Elife; 2018 Dec; 7():. PubMed ID: 30526855
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutations of PREX2 gene in patients with hepatocellular carcinoma.
Yang MH; Yen CH; Chen YF; Fang CC; Li CH; Lee KJ; Lin YH; Weng CH; Liu TT; Huang SF; Teh BT; Chen YA
Sci Rep; 2019 Feb; 9(1):2552. PubMed ID: 30796242
[TBL] [Abstract][Full Text] [Related]
11. Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Horrigan SK;
Elife; 2017 Jan; 6():. PubMed ID: 28100392
[TBL] [Abstract][Full Text] [Related]
12. Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Shan X; Fung JJ; Kosaka A; Danet-Desnoyers G;
Elife; 2017 Jun; 6():. PubMed ID: 28653617
[TBL] [Abstract][Full Text] [Related]
13. Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Mantis C; Kandela I; Aird F;
Elife; 2017 Jan; 6():. PubMed ID: 28100395
[TBL] [Abstract][Full Text] [Related]
14. PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion.
Mense SM; Barrows D; Hodakoski C; Steinbach N; Schoenfeld D; Su W; Hopkins BD; Su T; Fine B; Hibshoosh H; Parsons R
Sci Signal; 2015 Mar; 8(370):ra32. PubMed ID: 25829446
[TBL] [Abstract][Full Text] [Related]
15. Replication Study: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.
Wang H; Radomska HS; Phelps MA;
Elife; 2020 Oct; 9():. PubMed ID: 33073769
[TBL] [Abstract][Full Text] [Related]
16. Replication Study: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology.
Kerwin J; Khan I;
Elife; 2020 Apr; 9():. PubMed ID: 32314732
[TBL] [Abstract][Full Text] [Related]
17. Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data.
Kandela I; Aird F;
Elife; 2017 Jan; 6():. PubMed ID: 28100397
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
[TBL] [Abstract][Full Text] [Related]
19. Replication Study: Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis.
Sheen MR; Fields JL; Northan B; Lacoste J; Ang LH; Fiering S;
Elife; 2019 Dec; 8():. PubMed ID: 31845647
[TBL] [Abstract][Full Text] [Related]
20. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.
Johnson DB; Lovly CM; Flavin M; Panageas KS; Ayers GD; Zhao Z; Iams WT; Colgan M; DeNoble S; Terry CR; Berry EG; Iafrate AJ; Sullivan RJ; Carvajal RD; Sosman JA
Cancer Immunol Res; 2015 Mar; 3(3):288-295. PubMed ID: 25736262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
